Independent equity research
Is Hims & Hers Health (HIMS) a Buy, Hold or Sell?
Hims & Hers Health — our independent, AI-built valuation and rating, in brief.
SELL (reduce)
12-mo fair value
$21.00
To fair value
−24%
By · report dated 2026-08-11 · fair value derived independently of the market price.
The thesis, in brief
Hims is buying its 38% headline growth with acquisitions and a permanent gross-margin reset — 76% to 64% in four quarters — and has produced negative cumulative free cash flow after stock comp since 2023; we are sellers unless gross margin stabilises above 62% and owner FCF turns positive by Q4 2026
How we value it
We value Hims & Hers Health using 10-yr DCF on owner FCF (FCF after SBC), cross-checked on EV/adj. EBITDA. The 12-month fair value is set from that intrinsic estimate first, then compared to the market to read the upside or downside — never anchored to the current price.
What the full report covers
- Business & moat + industry cycle
- Earnings quality & normalized EPS
- Returns on capital (ROIC vs WACC)
- Balance-sheet safety
- Two independent valuations (DCF + multiples)
- Bear / base / bull fair values
- Earnings-call analysis
- Insider activity & positioning
- Technicals (RSI / ADX)
- A falsifiable thesis
Read the full Hims & Hers Health report
The complete model, the scenarios, and every number behind the call — plus other names across the coverage. One subscription, cancel anytime.